Response Genetics, Inc
RGDXQ
$0.00
$0.000.00%
| Weiss Ratings | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -19.41 | |||
| Price History | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -- | |||
| 30-Day Total Return | -- | |||
| 60-Day Total Return | -- | |||
| 90-Day Total Return | -- | |||
| Year to Date Total Return | -- | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -99.96% | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Oct 30, 2024 | |||
| 52-Week High Price (Date) | Oct 30, 2024 | |||
| Valuation | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 38.00 | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -- | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | -- | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 323-224-3900 | |||
| Address | 1640 Marengo Street Los Angeles, CA 90033 | |||
| Website | www.responsegenetics.com | |||
| Country | United States | |||
| Year Founded | 1999 | |||
| Profitability | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -82.15% | |||
| Profit Margin | -85.53% | |||
| Management Effectiveness | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -67.88% | |||
| Return on Equity | -- | |||
| Income Statement | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 16.62M | |||
| Total Revenue (TTM) | 16.62M | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 6.25M | |||
| EBITDA (TTM) | -12.84M | |||
| EBIT (TTM) | -13.65M | |||
| Net Income (TTM) | -14.21M | |||
| Net Income Avl. to Common (TTM) | -14.21M | |||
| Total Revenue Growth (Q YOY) | -2.68% | |||
| Earnings Growth (Q YOY) | -14.67% | |||
| EPS Diluted (TTM) | -0.37 | |||
| EPS Diluted Growth (Q YOY) | -14.48% | |||
| Balance Sheet | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.73M | |||
| Cash Per Share (Q) | $0.04 | |||
| Total Current Assets (Q) | 8.76M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -4.94M | |||
| Current Ratio (Q) | 1.795 | |||
| Book Value Per Share (Q) | -- | |||
| Total Assets (Q) | -- | |||
| Total Current Liabilities (Q) | 4.88M | |||
| Total Debt (Q) | -- | |||
| Total Liabilities (Q) | -- | |||
| Total Common Equity (Q) | -4.94M | |||
| Cash Flow | RGDXQ - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -59.90K | |||
| Cash from Financing (TTM) | 9.92M | |||
| Net Change in Cash (TTM) | -3.22M | |||
| Levered Free Cash Flow (TTM) | -8.32M | |||
| Cash from Operations (TTM) | -13.09M | |||
